Results 91 to 100 of about 1,853,915 (311)

Prognosis of patients with hepatocellular carcinoma. Validation and ranking of established staging-systems in a large western HCC-cohort. [PDF]

, 2012
HCC is diagnosed in approximately half a million people per year, worldwide. Staging is a more complex issue than in most other cancer entities and, mainly due to unique geographic characteristics of the disease, no universally accepted staging system ...
Göke, Burkhard, Kolligs, Frank T., Lamerz, Rolf, Nagel, Dorothea, Nickel, Thomas, Rentsch, Markus, Sappl, Julia, Stieber, Petra, Straub, Gundula, Winkel, Mark op den, Winkel, Philip op den, Zech, Christoph J.   +11 more
core   +7 more sources

Emerging roles and the regulation of aerobic glycolysis in hepatocellular carcinoma

Journal of experimental & clinical cancer research : CR, 2020
Liver cancer has become the sixth most diagnosed cancer and the fourth leading cause of cancer death worldwide. Hepatocellular carcinoma (HCC) is responsible for up to 75–85% of primary liver cancers, and sorafenib is the first targeted drug for advanced
Jiao Feng, Jingjing Li, Liwei Wu, Qiang Yu, J. Ji, Jianye Wu, Wei-qi Dai, Chuanyong Guo   +7 more
semanticscholar   +1 more source

Inhibitor of DNA binding‐1 is a key regulator of cancer cell vasculogenic mimicry

Molecular Oncology, EarlyView.
Elevated expression of transcriptional regulator inhibitor of DNA binding 1 (ID1) promoted cancer cell‐mediated vasculogenic mimicry (VM) through regulation of pro‐angiogenic and pro‐cancerous genes (e.g. VE‐cadherin (CDH5), TIE2, MMP9, DKK1). Higher ID1 expression also increased metastases to the lung and the liver.
Emma J. Thompson, Emma L. Dorward, Kristyn Jurrius, Nathalie Nataren, Markus Tondl, Kay K. Myo Min, Michaelia P. Cockshell, Anahita Fouladzadeh, John Toubia, Mark DeNichilo, Delphine Merino, Claudine S. Bonder   +11 more
wiley   +1 more source

Cancer-Associated Thrombosis in Cirrhotic Patients with Hepatocellular Carcinoma. [PDF]

, 2018
It is common knowledge that cancer patients are more prone to develop venous thromboembolic complications (VTE). It is therefore not surprising that patients with hepatocellular carcinoma (HCC) present with a significant risk of VTE, with the portal vein
Burra, P, Campello, E, Russo, Fp., Simioni, P, Spiezia, L, Zanetto, A   +5 more
core   +1 more source

TRIM55 restricts the progression of hepatocellular carcinoma through ubiquitin-proteasome-mediated degradation of NF90

Cell Death Discovery
Hepatocellular carcinoma (HCC) is a prevalent malignant tumor worldwide. Tripartite motif containing 55 (TRIM55), also known as muscle-specific ring finger 2 (Murf2), belongs to the TRIM protein family and serves as an E3 ligase.
Changhong Luo, Yuyan Lu, Qinliang Fang, Jing Lu, Ping Zhan, Wenqing Xi, Jinzhu Wang, Xijun Chen, Qin Yao, Fuqiang Wang, Zhenyu Yin, Chengrong Xie   +11 more
doaj   +1 more source

HNF-4α inhibits hepatocellular carcinoma cell proliferation through mir-122-adam17 pathway.

PLoS ONE, 2020
Hepatocellular carcinoma (HCC) is one of the most common human cancers, its prevalence and severity need us to discover novel early diagnostic biomarkers and new therapeutic strategies. MicroRNA-122 is the most abundant microRNA in the liver, and acts as
Guang Yang, Min Zhang, Yawei Zhao, Yue Pan, Mujie Kan, Jing Li, Kan He, Xuewen Zhang   +7 more
doaj   +1 more source

Aberrant expression of nuclear prothymosin α contributes to epithelial‐mesenchymal transition in lung cancer

Molecular Oncology, EarlyView.
Nuclear prothymosin α inhibits epithelial‐mesenchymal transition (EMT) in lung cancer by increasing Smad7 acetylation and competing with Smad2 for binding to SNAI1, TWIST1, and ZEB1 promoters. In early‐stage cancer, ProT suppresses TGF‐β‐induced EMT, while its loss in the nucleus in late‐stage cancer leads to enhanced EMT and poor prognosis.
Liyun Chen, Chung‐Teng Wang, Jia‐Ming Chang, Ai‐Li Shiau, Gia‐Shing Shieh, Yau‐Lin Tseng, Yi‐Ting Yen, Tang‐Hsiu Huang, Li‐Hsin Cheng, Yu‐Chih Wu, Chao‐Liang Wu, Bing‐Hua Su, Pensee Wu   +12 more
wiley   +1 more source

Prospective Phase II trial of drug-eluting bead chemoembolization for liver transplant candidates with hepatocellular carcinoma and marginal hepatic reserve. [PDF]

, 2019
Purpose: To determine whether chemoembolization using drug-eluting beads (DEB-TACE) is safe and effective for liver transplantation candidates with liver-limited hepatocellular carcinoma (HCC) without vascular invasion and baseline hepatic dysfunction ...
Fidelman, Nicholas, Johanson, Curt, Kelley, R Kate, Kerlan, Robert K, Kohi, Maureen P, Kohlbrenner, Ryan M, Kolli, K Pallav, Lehrman, Evan D, Roberts, John P, Taylor, Andrew G, Yao, Francis Y   +10 more
core   +1 more source

Molecular testing for the clinical diagnosis of fibrolamellar carcinoma. [PDF]

, 2018
Fibrolamellar carcinoma has a distinctive morphology and immunophenotype, including cytokeratin 7 and CD68 co-expression. Despite the distinct findings, accurate diagnosis of fibrolamellar carcinoma continues to be a challenge.
Alves, Venancio Af, Cruise, Michael W, Ferrell, Linda, Gill, Ryan M, Graham, Rondell P, Greipp, Patricia T, Jain, Dhanpat, Jin, Long, Kakar, Sanjay, Kerr, Sarah E, Lam-Himlin, Dora, Longerich, Thomas, Nart, Deniz, Roberts, Lewis R, Roessler, Stephanie, Rustin, Jeanette G, Salaria, Safia N, Schirmacher, Peter, Solomon, David A, Sukov, William R, Terracciano, Luigi, Torbenson, Michael S, Wang, Xiaoke, Waterhouse, Emily, Yeh, Matthew M, Yilmaz, Funda, Zaid, Nida, Zreik, Riyam T   +27 more
core   +1 more source

Relationship between retinol metabolism and hepatocellular carcinoma: a comprehensive analysis of Mendelian randomization, prognostic characteristic and experiment

Discover Oncology
Purpose Retinol metabolism is intricately linked to the occurrence and progression of hepatocellular carcinoma (HCC); however, the precise pathogenic relationship between them remains elusive. The aim of this study was to elucidate the characteristics of
Fuqing Chen, Yifan Cai, Jianyin Zhou
doaj   +1 more source